- Home
- PSTV vs NRXP Comparison
PSTV vs NRXP Comparison
Compare PSTV & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSTV | NRXP |
|---|---|---|
| Founded | 1996 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.4M | 54.2M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | PSTV | NRXP |
|---|---|---|
| Price | $0.25 | $1.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $6.75 | ★ $31.50 |
| AVG Volume (30 Days) | ★ 3.9M | 497.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,213,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $46.30 | $847.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $1.58 |
| 52 Week High | $2.08 | $3.84 |
Technical Indicators
Market Signals| Indicator | PSTV | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 37.09 | 49.93 |
| Support Level | $0.21 | $1.65 |
| Resistance Level | $0.32 | $1.99 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 6.51 | 63.49 |
Price Performance
Historical ComparisonAbout PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.